These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 1654556)
1. Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase. George FW; Russell DW; Wilson JD Proc Natl Acad Sci U S A; 1991 Sep; 88(18):8044-7. PubMed ID: 1654556 [TBL] [Abstract][Full Text] [Related]
2. Differential effect of 5 alpha-reductase inhibition and castration on androgen-regulated gene expression in rat prostate. Rittmaster RS; Magor KE; Manning AP; Norman RW; Lazier CB Mol Endocrinol; 1991 Jul; 5(7):1023-9. PubMed ID: 1719382 [TBL] [Abstract][Full Text] [Related]
3. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Dadras SS; Cai X; Abasolo I; Wang Z Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152 [TBL] [Abstract][Full Text] [Related]
6. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Hirsch KS; Jones CD; Audia JE; Andersson S; McQuaid L; Stamm NB; Neubauer BL; Pennington P; Toomey RE; Russell DW Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5277-81. PubMed ID: 8389478 [TBL] [Abstract][Full Text] [Related]
7. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B Prostate; 1993; 22(1):43-51. PubMed ID: 8381228 [TBL] [Abstract][Full Text] [Related]
8. The clinical development of a 5 alpha-reductase inhibitor, finasteride. Stoner E J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660 [TBL] [Abstract][Full Text] [Related]
9. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat. George FW; Johnson L; Wilson JD Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651 [TBL] [Abstract][Full Text] [Related]
10. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review. Imperato-McGinley J Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167 [TBL] [Abstract][Full Text] [Related]
11. Effects of 5 alpha-reductase inhibitors on intraprostatic androgens in the rat. di Salle E; Giudici D; Biagini L; Cominato C; Briatico G; Panzeri A J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):381-5. PubMed ID: 7626485 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707 [TBL] [Abstract][Full Text] [Related]
13. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. George FW Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585 [TBL] [Abstract][Full Text] [Related]
14. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Geller J J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965 [TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors. Bratoeff E; Cabeza M; Pérez-Ornelas V; Recillas S; Heuze I J Steroid Biochem Mol Biol; 2008 Sep; 111(3-5):275-81. PubMed ID: 18644453 [TBL] [Abstract][Full Text] [Related]
17. Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. Thigpen AE; Russell DW J Biol Chem; 1992 Apr; 267(12):8577-83. PubMed ID: 1314830 [TBL] [Abstract][Full Text] [Related]
18. FCE 28260, a new 5 alpha-reductase inhibitor: in vitro and in vivo effects. Giudici D; Briatico G; Cominato C; Zaccheo T; Iehlè C; Nesi M; Panzeri A; di Salle E J Steroid Biochem Mol Biol; 1996 Jun; 58(3):299-305. PubMed ID: 8836165 [TBL] [Abstract][Full Text] [Related]
19. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. Geller J; Sionit L J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893 [TBL] [Abstract][Full Text] [Related]
20. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]